# A First-in-human Study of SCTB35 in Patients With Relapse/Refractory B-cell Non-Hodgkin Lymphoma

> **NCT06318884** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Sinocelltech Ltd.** · enrollment: 76 (estimated)

## Conditions studied

- Non-Hodgkin Lymphoma, B-cell

## Interventions

- **DRUG:** SCTB35 injection

## Key facts

- **NCT ID:** NCT06318884
- **Lead sponsor:** Sinocelltech Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-04
- **Primary completion:** 2026-10
- **Final completion:** 2027-12
- **Target enrollment:** 76 (ESTIMATED)
- **Last updated:** 2024-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06318884

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06318884, "A First-in-human Study of SCTB35 in Patients With Relapse/Refractory B-cell Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06318884. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*